Orchestra BioMed prices public offering of 15 M shares
Orchestra BioMed announced the pricing of an underwritten public offering of 15 M common shares at $5.00 per share. The company expects gross proceeds of $75 million before underwriting discounts and commissions. Proceeds are earmarked to fund the AVIM Therapy and Virtue SAB clinical programs and general corporate purposes. The offering includes a 30‑day option for underwriters to purchase up to an additional 15 % of the shares.
Why it matters
The $75 million of gross proceeds will provide capital to advance the company’s hypertension and coronary artery disease trials, potentially extending its cash runway and supporting research milestones.
Key facts
- 1The offering consists of 15 M common shares. tradingview.com
- 2Shares are priced at $5.00 each. tradingview.com
- 3Gross proceeds are expected to be $75 million before discounts and commissions. tradingview.com
- 4Piper Sandler and TD Cowen are joint bookrunning managers. investing.com
- 5Underwriters have a 30‑day option to purchase up to an additional 15 % of the shares sold. investing.com
- 6The offering is subject to market and other conditions and is expected to close on Nov. 9, 2026. tradingview.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.